Lyfstone
Lyfstone is a Netherlands-based med-tech company that sells a CE-IVD lateral flow rapid test for calprotectin in synovial fluid, enabling orthopedic surgeons to rule out periprosthetic joint infection in 15 minutes at the point of care, distributed across 13 European countries.
- Company typePrivate
- Founded1999
- HeadquartersAbcoude, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lyfstone does
Lyfstone is a Netherlands-based medical diagnostics company that develops and commercializes a point-of-care biomarker test for periprosthetic joint infection (PJI), a complication of hip and knee arthroplasty. The company's flagship product, Lyfstone® Calprotectin, is a CE-IVD labeled lateral flow rapid test that detects calprotectin levels in synovial fluid from a 20 μl sample and produces results in approximately 15 minutes. The test is paired with the Lyfstone® Reader mobile application (iOS and Android) and a web portal that together convert the lateral flow cassette image into a quantitative result for the clinician.
The product has been clinically validated across three independent international diagnostic frameworks (MSIS 2013, 2018 ICM, and EBJIS), with peer-reviewed evidence from Vienna (169 patients), Cleveland Clinic (123 patients), and Munich (137 patients). Reported performance ranges from 93.2% to 98.2% sensitivity and 95.7% to 100% specificity depending on the criteria set used. The assay is positioned as a faster, lower-cost alternative to traditional lab-based PJI diagnostics (cultures, blood tests, imaging), enabling same-visit decision-making for orthopedic surgeons at consultation, pre-operative, and peri-operative stages.
Lyfstone operates a distributor-led commercial model across 13 European countries (Austria, Belgium, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, UK, and Spain) through 12 named national medical device distribution partners. Revenue is generated from hardware sales of test kits and associated consumables; pricing is not publicly disclosed and orders flow through distributors. The company is privately held, headquartered in Abcoude, Netherlands (Lyfstone BV), with a Norwegian entity (Lyfstone AS), and operates with 1-10 employees. The LinkedIn page is registered under Orthogenics AS (Hungary), and Calpro AS (Norway) acts as the data processor for the Lyfstone app and portal.
Lyfstone firmographics
Firmographics- Name
- Lyfstone
- Legal name
- Lyfstone BV
- Website
- https://lyfstone.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lyfstone is a Netherlands-based med-tech company that sells a CE-IVD lateral flow rapid test for calprotectin in synovial fluid, enabling orthopedic surgeons to rule out periprosthetic joint infection in 15 minutes at the point of care, distributed across 13 European countries.
- Ownership category
- akta.pro rank
Lyfstone industry classification
Industry- Product category
- In Vitro Diagnostics (Orthopedic Point-of-Care Testing)
- NAICS
- Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category) (HLAHAOAH)
- akta.pro secondary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Lyfstone is headquartered
LocationHeadquarters
- HQ city
- Abcoude
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
Lyfstone business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Test Kit Sales: Sale of Lyfstone Calprotectin rapid test kits to healthcare providers through distributor network. Professional solution for orthopedic surgeons. The test requires additional equipment including laboratory pipettes (20μl and 80μl) and aerosol-filter pipette tips.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Lyfstone product offering
Product offeringCore offering
Lyfstone develops, manufactures, and sells the Lyfstone® Calprotectin Point-of-Care rapid test, a CE-IVD labeled lateral flow assay that detects calprotectin levels in synovial fluid to rule out periprosthetic joint infection (PJI) in hip and knee arthroplasty patients within approximately 15 minutes. The test is paired with the Lyfstone® Reader mobile application (iOS/Android) and the Lyfstone® Web Portal, which together convert the lateral flow cassette into a quantitative diagnostic result for orthopedic surgeons and healthcare providers across European markets.
Product overview
Lyfstone offers a unified diagnostic solution centered on the Lyfstone® Calprotectin rapid test, a CE-IVD labeled point-of-care lateral flow assay for detecting periprosthetic joint infection. The product portfolio consists of the Lyfstone® Calprotectin test kit as the core offering, paired with the Lyfstone® Reader mobile application (iOS/Android) that enables quantitative result analysis via smartphone camera, and the Lyfstone® Web Portal for account and clinic management. The system provides orthopedic surgeons with rapid, bedside PJI diagnostics from synovial fluid in approximately 15 minutes.
Differentiator
Problem solved
Functional benefit
Brands
- Lyfstone Reader: Mobile application for scanning and quantifying results from the Lyfstone Calprotectin test.
Products and services
- Lyfstone® Calprotectin Point-of-Care Rapid Test A CE-IVD labeled Point-of-Care lateral flow rapid test that quantitatively detects calprotectin levels in synovial fluid to rule out periprosthetic joint infection (PJI) in hip and knee arthroplasty patients. Requires only 20 µl of synovial fluid, delivers quantitative results in 15 minutes at the bedside, and is clinically validated against MSIS 2013, 2018 ICM, and EBJIS criteria. Sold to orthopedic surgeons, hospitals, and clinics via national medical device distributors.
- Lyfstone® Reader Mobile Application A smartphone application (iOS/Android) that scans the Lyfstone Calprotectin lateral flow cassette via the phone camera, analyzes control and test lines using pre-programmed ratio-based algorithms, and delivers quantitative calprotectin concentration results. Users log in with their clinic Lyfstone account to access the portal system. Available for download on the Apple App Store and Google Play Store.
- Lyfstone® Web Portal A web-based portal where clinic users log in with their Lyfstone account credentials to manage test accounts, view historical results, and administer their clinic's use of the Lyfstone Calprotectin test.
Quantifiable outcome
- 98.1% sensitivity, 95.7% specificity, 98.5% NPV using MSIS 2013 criteria
- +3 more outcomes
Companies that use Lyfstone
Customer profileSegments1 record
Ideal customer profiles1 record
Lyfstone technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Lyfstone partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- Endocon GmbHcoreEndocon GmbH (69257 Wiesenbach In der Au 5, Germany) serves as the national distributor for Lyfstone Calprotectin test kits in Germany. Healthcare providers in Germany contact Endocon for ordering and pricing information.
- Norimplant AScoreNorimplant AS (Strandflatveien 39, N-4018 Stavanger, Norway) distributes Lyfstone Calprotectin test kits in Norway. Contact: +47 909 40 369.
- Selinion Medical B.V.coreSelinion Medical B.V. (Stationsplein 105, 5211 's-Hertogenbosch, Netherlands) distributes Lyfstone products in the Netherlands. Contact: +31 (0)73 850 93 05.
- Histone MedicalcoreHistone Medical (82, Route de Bayonne, 31300 Toulouse, France) distributes Lyfstone Calprotectin test kits in France. Contact: +33 05 34 51 09 18.
- Assut Europe S.P.AcoreAssut Europe S.P.A (Via G. Gregoraci, 12 00173 Rome, Italy) distributes Lyfstone Calprotectin test kits in Italy. Contact: +39 06 72677348.
- WellWell Medical LtdcoreWellWell Medical Ltd (25 Currie Road, Northampton NN2 6JH, UK) distributes Lyfstone Calprotectin test kits in the United Kingdom. Contact: +44 (0) 1604 714 222.
- MBA Surgical Empowerment PortugalcoreMBA SURGICAL EMPOWERMENT Portugal (Rua Manuel Pinto Azevedo 74, 2º A. 4100 320 Porto) distributes Lyfstone products in Portugal. Contact: +351 226 166 060 / +351 226 166 069.
- MBA Surgical Empowerment SpaincoreMba Surgical Empowerment Spain (Avda. Jardín Botánico 1345, Silos del Intra, 33203 Gijón, Asturias, España) distributes Lyfstone products in Spain. Contact: +34 985 195 505 / +34 985 373 452.
- Prime BiosciencescorePrime Biosciences (18, Lemesou Str. 17341 Athens, Greece) distributes Lyfstone Calprotectin test kits in Greece.
- Synergolab LtdcoreSynergolab Ltd (Baber str. 5. 8000 Szekesfehervar, Hungary) distributes Lyfstone Calprotectin test kits in Hungary. Contact: +36 1 787 47 05.
- Ralf Medical Sp z.o.o.coreRalf Medical Sp z.o.o. (ul. Sieradzka 10 lok. 2, 60-163 Poznań, Poland) distributes Lyfstone Calprotectin test kits in Poland. Contact: +48 600 331 180.
- Lyfstone BVminorLyfstone BV (Papehof 49 1391 BE Abcoude, Netherlands) handles direct sales for countries without a national distributor. Contact: +36 70 326 1276 or [email protected].
Scale indicators5 records
Recent moves3 records
Expansion highlights4 records
Lyfstone competitors and assessment
Company assessmentBroad incumbents
- Abbott Rapid Diagnostics: Abbott offers a broad portfolio of rapid point-of-care diagnostic tests across multiple indications through its Alere-acquired platform. Competes in POC diagnostics infrastructure and distribution, with potential to enter adjacent rapid calprotectin testing through existing channels.
- Roche Diagnostics: Roche Diagnostics offers cobas and Elecsys diagnostic platforms that include calprotectin and inflammatory marker assays in central lab settings. Competes with Lyfstone in calprotectin measurement via established laboratory immunoassays with broad hospital penetration and reimbursement.
- bioMérieux: bioMérieux is a global in vitro diagnostics leader with broad microbiology and infection diagnostics portfolios (VITEK, BioFire, BACT/ALERT). Competes with Lyfstone via its comprehensive hospital infection diagnostics offering, including solutions applicable to orthopedic PJI workflows.
- QuidelOrtho: QuidelOrtho is a major in vitro diagnostics manufacturer offering Triage and Sofia rapid diagnostic platforms for multiple point-of-care indications. Competes in the rapid lateral flow and POC testing category with established US distribution, FDA-cleared products, and broad reimbursement coverage.
- Zimmer Biomet (Synovasure): Zimmer Biomet offers Synovasure, an alpha-defensin lateral flow test for PJI diagnosis, marketed alongside its orthopedic implant portfolio. Targets the same orthopedic surgeon customer base for periprosthetic joint infection diagnosis, but operates as a large diversified orthopedic incumbent with established US distribution and reimbursement.
Others
- Calpro AS: Calpro AS is the developer of the CALPREST and other fecal calprotectin ELISA tests for IBD, and is referenced as the data processor for Lyfstone's app and portal services. Operates in the broader calprotectin biomarker space but focused on stool/gastrointestinal indications rather than synovial fluid PJI diagnostics.
Emerging players
- Curetis (OpGen): OpGen (which acquired Curetis) develops molecular diagnostic platforms (Unyvero) for severe bacterial infections, including PJI applications. Competitor in the rapid PJI diagnostic space using a different technology approach (molecular/PCR-based) compared to Lyfstone's lateral flow calprotectin test.
- T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics (T2Bacteria, T2Candida) for sepsis and infectious disease. Competes in the rapid infection diagnostics space with emerging relevance to orthopedic and PJI applications through hospital infection management workflows.
Direct peers
- Bühlmann Laboratories: Bühlmann Laboratories is the established market leader in calprotectin diagnostics, offering laboratory-based ELISA and quantitative lateral flow calprotectin tests for inflammatory conditions. Direct competitor to Lyfstone Calprotectin in the calprotectin biomarker space, with broader indication coverage including IBD.
- Alpha-defensin test developers (CD Diagnostics, Ethicon): CD Diagnostics and Ethicon offer alpha-defensin-based PJI diagnostic tests that compete directly with Lyfstone's calprotectin-based approach for the same clinical use case of ruling out periprosthetic joint infection at the bedside or in the lab.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Lyfstone social profiles
Digital presenceLyfstone compliance and trust
Trust signalCompliance1 record
Lyfstone financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lyfstone leadership team
Management profileNumber of profiles
Lyfstone funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lyfstone M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lyfstone
What does Lyfstone do?
Lyfstone develops, manufactures, and sells the Lyfstone® Calprotectin Point-of-Care rapid test, a CE-IVD labeled lateral flow assay that detects calprotectin levels in synovial fluid to rule out periprosthetic joint infection (PJI) in hip and knee arthroplasty patients within approximately 15 minutes. The test is paired with the Lyfstone® Reader mobile application (iOS/Android) and the Lyfstone® Web Portal, which together convert the lateral flow cassette into a quantitative diagnostic result for orthopedic surgeons and healthcare providers across European markets.
Is Lyfstone a public or private company?
Lyfstone is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Lyfstone founded?
Lyfstone was founded in 1999. It employs 1 to 10 people.
Where is Lyfstone based?
Lyfstone is headquartered in Abcoude, Netherlands, in the Europe region.
How does Lyfstone make money?
One revenue line is on record: test Kit Sales.
Who are Lyfstone's main competitors?
Broad incumbents on record are Abbott Rapid Diagnostics, Roche Diagnostics, bioMérieux, QuidelOrtho and Zimmer Biomet (Synovasure). Calpro AS is listed as an others. Emerging players are Curetis (OpGen) and T2 Biosystems. Direct peers are Bühlmann Laboratories and Alpha-defensin test developers (CD Diagnostics, Ethicon).
Does Lyfstone have an API?
No public API is recorded for Lyfstone.
What industry is Lyfstone in?
Lyfstone's product category is In Vitro Diagnostics (Orthopedic Point-of-Care Testing). Its primary akta.pro industry code is HLAHAOAH, Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 621511 and its SIC code is 2835.